Anti-human beta-amyloid 1-12 mAb 3C4
Aβ peptides, generated from amyloid precursor protein (APP), are produced in all healthy tissues and may regulate synaptic activity, neural plasticity, and microbial defense in the CNS. In Alzheimer’s disease, however, Aβ accumulates and aggregates into amyloid plaques in memory- and cognition-related brain regions.
The antibody is produced exclusively from hybridoma and purified through one-step purification with Protein-A affinity chromatography.
In stock
Delivery time: 2-5 days
From: 326,00 € Excl. VAT and delivery costs
Please contact us for larger quantities.
Aβ peptides, generated from amyloid precursor protein (APP), are produced in all healthy tissues and may regulate synaptic activity, neural plasticity, and microbial defense in the CNS. In Alzheimer’s disease, however, Aβ accumulates and aggregates into amyloid plaques in memory- and cognition-related brain regions. The “amyloid cascade hypothesis” proposes that disease arises from imbalances in Aβ production, aggregation, and clearance. While age and genetic mutations contribute, the precise mechanisms are not yet understood.
The clone 3C4 is a Monoclonal Mouse antibody against Human B−amyloid 1-12, Beta-Amyloid, Amyloid-Beta (Uniprot: P05067 · A4, amyloid-beta precursor protein).
The antibody is produced exclusively from hybridoma and purified through one-step purification with Protein-A affinity chromatography.
| Product-ID: | INV4000063 |
|---|---|
| Clone: | 3C4 |
| Immunogen: | Animals were immunized with Synthetic peptide VKMDAEFRHDSGY |
| Host: | Mouse |
| Clonality: | Monoclonal |
| Isotype: | IgG1k |
| Formulation: | Clear Liquid, PBS, pH 7.4 |
| Concentration: | > 1.0 mg/ml |
| Purity: | > 95% by SDS-PAGE |
| Sizes available: | 0.1 mg and 1.0 mg |
| Storage: | at - 20 °C (repeated thawing and freezing should be avoided) |
| Tested application(s): | ELISA, Western Blot, Immunhistochemistry |
The product is for research use only and not for use in diagnostic or therapeutic procedures.
Additional information
| Literature | [1] – Petersen RC, Graf A, Atkins AS, Brys M, Murphy J, Miller DS, Reyderman L, Siemers E, Smith J, Carrillo MC, Weber CJ. Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer’s disease. Alzheimers Dement (N Y). 2025 May 24;11(2):e70069. doi: 10.1002/trc2.70069. PMID: 40417267; PMCID: PMC12102660. |
|---|---|
| Document | |
| Protocol | |
| Notice | The product is for research use only and not for use in diagnostic or therapeutic procedures. |
You must be logged in to post a review.
Reviews
There are no reviews yet.